---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-071745"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-06-25T11:31:00+00:00"
generated_at: "2026-06-25T11:35:33.460465+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040

## Summary
- USPTO granted patent for IHL-42X composition and methods for OSA; baseline expiry 9 July 2040.
- Company exploring patent term extension after potential FDA approval to lengthen exclusivity.
- IHL-42X has FDA Fast Track designation, positive Phase II data; DReAMzz study nearing patient recruitment with site IRB approvals and DEA registrations.
- CEO states patent validates IHL-42X as differentiated asset targeting billion-person OSA market with poor adherence.

## SEC filing metadata
- accession: 0001213900-26-071745
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-06-25T11:31:00+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026071745/0001213900-26-071745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026071745/ea0295769-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-071745
- JSON: https://secwatch.observer/filing/0001213900-26-071745.json
- Plain text: https://secwatch.observer/filing/0001213900-26-071745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.